Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

LaMarche, MJ; Acker, M; Argintaru, A; Bauer, D; Boisclair, J; Chan, HM; Chen, CHT; Chen, YN; Chen, ZL; Deng, Z; Dore, M; Dunstan, D; Fan, JM; Fekkes, P; Firestone, B; Fodor, M; Garcia-Fortanet, J; Fortin, PD; Fridrich, C; Giraldes, J; Glick, M; Grunenfelder, D; Hao, HX; Hentemann, M; Ho, S; Jouk, A; Kang, ZB; Karki, R; Kato, M; Keen, N; Koenig, R; LaBonte, LR; Larrow, J; Liu, G; Liu, SM; Majumdar, D; Mathieu, S; Meyer, MJ; Mohseni, M; Ntaganda, R; Palermo, M; Perez, L; Pu, MY; Ramsey, T; Reilly, J; Sarver, P; Sellers, WR; Sendzik, M; Shultz, MD; Slisz, J; Slocum, K; Smith, T; Spence, S; Stams, T; Straub, C; Jr, VT; Toure, BB; Towler, C; Wang, P; Wang, HY; Williams, SL; Yang, F; Yu, B; Zhang, JH; Zhu, SZN

LaMarche, MJ (corresponding author), Novartis Pharmaceut, Global Discovery Chem, Cambridge, MA 02139 USA.

JOURNAL OF MEDICINAL CHEMISTRY, 2020; 63 (22): 13578

Abstract

SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell growth and differentiation via the MAPK signalin......

Full Text Link